TABLE 1.
Proliferative responses of leprosy patient and control PBMCs to peptides selected on the grounds of a distinct sequence and pronounced binding to HLA-DR molecules
| Peptide | Binding to purified proteins of HLA-DRb | No. of respondersc/total no. (%)
|
|
|---|---|---|---|
| Healthy subjects | TT/BT leprosy patients | ||
| 26–40 (0)a | 1, 15, 6, 7, 8 | NT | 3/14 (21) |
| 36–50 (1) | 4, 6, 9 | NT | 1/14 (7) |
| 41–55 (1) | B5, 6, 7 | 2/9 (22) | 5/29 (17) |
| 9/14 (64)d | 3/8 (38)d | ||
| 86–100 (2) | 6, 7, 8 | NT | 2/14 (14) |
| 141–155 (5) | 15 | 2/6 (33) | 3/10 (30) |
| 176–190 (1) | 1, B5, 4, 5, 6, 7, 8 | 1/3 (33) | 4/10 (40) |
| 206–219 (5) | 1, 15, B5, 6, 7, 8 | 5/9 (55) | 12/31 (39) |
| 9/18 (50)d | 4/8 (50)d | ||
| 216–230 (4) | B5 | 0/3 (0) | 1/10 (10) |
| 226–240 (3) | 6, 8 | NT | 1/15 (7) |
| 231–245 (1) | B5, 6, 8 | 2/9 (22) | 6/20 (30) |
| 241–255 (0) | 15, 8 | 1/6 (17) | 1/10 (10) |
| 266–280 (5) | 6, 8 | 3/6 (50) | 5/10 (50) |
| 8/12 (66)d | 5/8 (63)d | ||
| 271–285 (4) | 15, B5, 6, 7 | NT | 1/15 (7) |
| 276–290 (1) | B5, 4, 6, 8, 9 | 0/9 (0) | 6/20 (30) |
a
Number of residues differing between M. leprae and M. avium.
b
IC50 of ≤100 μM or <10 μM for those in bold.
c
SI, >2.0. NT, not tested.
d
Tested patients and controls were from London; all others were from India.